share_log

京新药业(002020.SZ):上半年公司销售费用3.84亿,同比下降3.63%

Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's sales expenses in the first half of the year were 0.384 billion, a year-on-year decrease of 3.63%.

Gelonghui Finance ·  Aug 16 06:34

On August 15, 2024, during a specific object investigation, Zhejiang Jingxin Pharmaceutical (002020.SZ) reported a sales expense of 0.384 billion in the first half of 2024, a 3.63% year-on-year decrease, and a 2.72 percentage point decrease in sales expense ratio. The company has achieved a continuous decrease in sales expenses these years, partly due to the company's emphasis on improving the efficiency of salespeople; on the other hand, it stems from the adjustment of the internal structure of sales expenses, and precise investment in controlling expenses. With the market promotion of Dexinisi, some expenses will inevitably increase, but the company will strive to control the sales expense ratio, hoping to continue to maintain stability or even decrease.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment